Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 1-27 (IGKV1-27) encodes the variable (V) region of the kappa light chain in human immunoglobulins (antibodies). This variable domain forms part of the antigen binding site, pairing with a variable heavy chain to create antibody specificity. The gene participates in the assembly of functional immunoglobulins through V-J (variable-joining) recombination in developing B cells, contributing to the diversity of the humoral immune response. IGKV1-27 is not a classical drug target or receptor but a gene segment involved in immune recognition processes. It plays a potential (though not unique) role in disease through its contribution to antibody specificity and, in rare cases, via RNA editing impacts observed in some cancers. No approved therapeutic drugs are known to interact directly with this variable region, though antibodies utilizing IGKV1-27 as part of their repertoire may have therapeutic or diagnostic uses.
Not applicable (antibodies as a class may be engineered to include this variable region for antigen binding, but IGKV1-27 itself is not directly drug-targeted)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 1-27 (IGKV1-27).